These mice exhibit augmented FLT3 (fms-related tyrosine kinase 3) signaling and inhibition of FLT3 kinase activity by quizartinib (AC220) effectively suppresses MPD development [41]. The gene discussed is FLT3; the disease is myeloproliferative disorder.